Adult Dosing

Hyperurecemia in gout

• Start 40 mg PO daily
• Increase to 80 mg daily if serum uric acid less than 6 mg/dL is not achieved after 2 wks of therapy
• Note: Give with gout flare prophylaxis such as NSAID or colchicine during treatment initiation as gout flares are frequently observed during initiation of anti-hyperuricemic agents

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Chronic management of hyperuricemia in patients with gout

• Hypersensitivity to any of the ingredients of the product
• Patients concomitantly treated with azathioprine, mercaptopurine

• N/A

Renal Dose Adjustment (Based on CrCl)

• Mild-moderate renal impairment (30-89 mL/min): No dose adjustments
• Severe renal impairment (<30 mL/min): Use with caution; dose adjustments not defined

Hepatic Dose Adjustment

• Child Pugh class A or B: No dose adjustments
• Child Pugh class C: Use with caution; dose adjustments not defined

• Not recommended for treating asymptomatic hyperuricemia
• Obtain target serum uric acid levels <6mg/dL after 2 weeks of initiating therapy
• Gout flares may occur with initiation of therapy with febuxostat. Give NSAID's or colchine concommitantly with initiation of therapy with febuxostat
• Febuxostat can cause increase in cardiovascular thromboembolic events (higher rate seen than with allopurinol); monitor for signs and symptoms of MI and stroke
• Serum transaminases (AST/ALT) may also be increased by febuxostat; recommend LFT's at 2 months, 4 months and periodically thereafter

Cautions: Use cautiously in

• Severe renal impairment
• Severe hepatic impairment

Uloric interacts with :

	Azasan
	Azathioprine
	Imuran
	Mercaptopurine
	Purinethol
	Purixan

Pregnancy Category:C

Breastfeeding: Safety Unknown; excreted in the milk of rats; because many drugs are excreted in human milk, manufacturer advises caution.

• GI: Liver Function Abnormalities, nausea
• MUSC: Arthralgia, gout flare
• DERM: Rash
• CV: MI, stroke
• CNS: Dizziness

• Xanthine oxidase inhibitor; reduces production of uric acid by inhibiting xanthine oxidase
• Metabolized by liver; CYP450 (by 1A2, 2C8, 2C9); glucuronidation (UGT1A1, 1A3, 1A9, 2B7) primarily
• Renally excreted: 49% (3% unchanged); feces: 45% (12% unchanged)
• Half-life: 5-8 hrs

US Trade Name(s)

• Uloric

US Availability

Uloric

• TABS: 40, 80 mg

Canadian Trade Name(s)

• Uloric

Canadian Availability

Uloric

• TABS: 80 mg

UK Trade Name(s)

• Adenuric

UK Availability

Adenuric

• TABS: 80, 120 mg

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Endocrine/Metabolic

Antigout Agents

Analgesics

Antigout Agents

Rheumatologic

Antigout Agents

Pricing data from www.DrugStore.com in U.S.A.

• Uloric 40 MG TABS [Bottle] (TAKEDA PHARMACEUTICALS)
  30 mg = $192.4
  90 mg = $547.04

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Uloric 40 MG Oral Tablet

Ingredient(s): Febuxostat

Imprint: TAP;40

Color(s): Green

Shape: Round

Size (mm): 9.00

Score: 1

Inactive Ingredient(s): lactose monohydrate / cellulose, microcrystalline / hydroxypropyl cellulose / croscarmellose sodium / silicon dioxide / magnesium stearate

Drug Label Author:
Takeda Pharmaceuticals America, Inc.

DEA Schedule:
Non-Scheduled

Drug Name: Uloric 80 MG Oral Tablet

Ingredient(s): Febuxostat

Imprint: TAP;80

Color(s): Green

Shape: Tear

Size (mm): 14.00

Score: 1

Inactive Ingredient(s): lactose monohydrate / cellulose, microcrystalline / hydroxypropyl cellulose / croscarmellose sodium / silicon dioxide / magnesium stearate

Drug Label Author:
Takeda Pharmaceuticals America, Inc.

DEA Schedule:
Non-Scheduled